Skip to content

Operating Income at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$642.9M+8.7%
AbbVie logo
AbbVieABBV
$3.99B+6.9%
Arrowhead Research logo
Arrowhead ResearchARWR
-$141.26M-137%
IQVIA logo
IQVIAIQV
$514M+3.6%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s operating income?
Apogee Therapeutics, Inc. (APGE) reported operating income of -$82.77M in Q1 2026.
How has Apogee Therapeutics, Inc.'s operating income changed year-over-year?
Apogee Therapeutics, Inc.'s operating income decreased by 31.2% year-over-year, from -$63.1M to -$82.77M.
What is the long-term trend for Apogee Therapeutics, Inc.'s operating income?
Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s operating income has grown at a 75.2% compound annual growth rate (CAGR), from -$93M to -$285.6M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.